Prevention of coronary heart disease in clinical practice - Commentary to recommendations of the Second Joint Task Force of European Societies on Coronary Prevention;Pravention koronarer herzerkrankungen in der klinischen praxis - Kommentar zu den Empfehlungen der Second Joint Task Force der Europiiischen Gesellschaften zur Koronarpravention

Wiener Medizinische Wochenschrift

Volumn 149, Issue 5-6, 1999, Pages 111-118

  Klein, W ^a   Maurer, G ^a   Patsch, J R ^b   Sandhofer, F ^c   Silberbauer, K ^d  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c I Medizinischen Abteilung   (Austria)

^d Abteilung für Innere Medezin   (Austria)

Author keywords

Atherosclerosis; Coronary heart disease; Primary prevention; Risk factors

Indexed keywords

ACETYLSALICYLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT;

CLINICAL PRACTICE; CORONARY RISK; HUMAN; ISCHEMIC HEART DISEASE; PRIMARY PREVENTION; REVIEW; RISK ASSESSMENT; RISK MANAGEMENT; SECONDARY PREVENTION; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; CORONARY ARTERY ATHEROSCLEROSIS; GERMANY; HYPERCHOLESTEROLEMIA; LIFESTYLE; MULTIMODALITY CANCER THERAPY; RISK FACTOR;

ANTICHOLESTEREMIC AGENTS; COMBINED MODALITY THERAPY; CORONARY ARTERIOSCLEROSIS; GERMANY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIFE STYLE; RISK FACTORS;

EID: 0032899003     PISSN: 00435341     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. (1) Ericsson CG, Hamsten A, Nilsson J, Grip L, Svane B, De Faire U: Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996;347:849-853.
2. (2) Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V, et al: Helsinky Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317: 1237-1245.
3. (3) Goldbourt U, Brunner D, Behar S, Reicher-Reiss H: Baseline characteristics of patients participating in the Bezafibrate Infarction Prevention (BIP) study. Eur Heart J 1998; 19 (suppl H): H42-H47 and personal communication by Kaplinsky.
4. (4) Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laako R: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-234.
5. (5) Hansson L, Zanchetti A, Carruthers SG, et al: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal treatment (HOT) randomized trial. Lancet 1998;351:1755-1762.
6. (6) He J, Whelton P, Vu B, Klag M: Aspirin and risk of hemorrhagic stroke. JAMA 1998;280:1930-1935.
7. (7) National Cholesterol Education Program: Second report of the expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel II). Circulation 1994;89: 1333-1145.
8. (8) Ohkubo T, Imai Y, Tsuji I, et al: Tokohu Univ Sch Med, Sendai, Japan. Reference values for 24-hour ambulatory blood pressure monitoring based on a prognostic criterion. The Ohasama Study. Hypertension 1998;32:255-259.
9. (9) O'Leary D, Polak J, Kronmal R, Manolio T, Burke G, Wolfson S: Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med 1999; 340: 14-22.
10. (10) Rubins HB, Robins SJ, Collins D: The Veterans Affairs High-Density Lipoprotein Intervention Trial: baseline characteristics of normocholesterolemic men with coronary artery disease and low levels of high-density lipoprotein cholesterol. Veterans Affairs Cooperative Study Group. Am J Cardiol 1996;78:572-575.
11. (11) Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335: 1001-1009.
12. (12) Steering Committee of the Physicians' Health Study Group: Final Report on the aspirin component of the ongoing physicians' health study. N Engl J Med 1989;321:129.
13. (13) The Post Coronary Artery Bypass Graft Trial Investigators: The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 1997;336: 153-162.
14. (14) The Sixth Report of the Joint National Committee on Prevention Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med 1997;157:2413-2445.
15. (15) Turner RC, Millins H, Neil HAW, Stratton IM, Manley SE, Matthews DR, Holman RR, for The United Kingdom Prospective Diabetes Study Group: Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospektive Diabetes Study (UKPDS:23). Br Med J 1998;316:823-828.
16. (16) World Health Organization - International Society of Hypertension Guidelines for the Management of Hypertension: Guidelines Subcommittee. J Hypertens 1999;17:151-183.
17. (17) Wood D, De Baker G, Faergeman O, Graham I, Mancia G, Pyörälä K, et al: Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Prevention of coronary heart disease in clinical practice. Eur Heart J 1998;19: 1434-1503.